Keros TherapeuticsKROS -0.55%30 PB Ratio is 0.75 as of Jun. 25, 2026, which is 82% below its 10-year median of 4.25. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Keros Therapeutics ranks better than 89.13% on this metric.
Keros Therapeutics Inc stock PB Ratio (=0.75) is close to 1-year low of 0.68.
The historical rank and industry rank for Keros Therapeutics's PB Ratio or its related term are showing as below:
KROS'
s PB Ratio Range Over the Past 10 Years
Min: 0.56 Med: 4.25 Max: 12.5
Current: 0.75
During the past 8 years, Keros Therapeutics's highest PB Ratio was 12.50. The lowest was 0.56. And the median was 4.25.
KROS's PB Ratio is ranked better than 89.13% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs KROS: 0.75
During the past 12 months, Keros Therapeutics's average Book Value Per Share Growth Rate was -19.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 15.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Keros Therapeutics was 15.50% per year. The lowest was -2.60% per year. And the median was 11.60% per year.
Back to Basics: PB Ratio
Keros Therapeutics (NAS:KROS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Keros Therapeutics PB Ratio Related Terms
Keros Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Keros Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Keros Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Keros Therapeutics (KROS) has a PB Ratio of 0.75 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Keros Therapeutics and its competitors. This is 82% below median its historical median of 4.25. Over the past decade, Keros Therapeutics' PB Ratio has ranged from 0.56 to 12.50. According to the industry distribution chart, Keros Therapeutics ranks #134 out of 1233 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Keros Therapeutics' PB Ratio too high?
Keros Therapeutics' current PB Ratio of 0.75 is 82% below median its 10-year median of 4.25. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 12.50. The Biotechnology industry median PB Ratio is 2.80. Keros Therapeutics' value of 0.75 is 73.2% below this industry median. Based on the distribution chart, Keros Therapeutics ranks #134 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' PB Ratio compare to RNA and RNAC?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #134 out of 1233 companies for PB Ratio. This places Keros Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Keros Therapeutics' value of 0.75 is 73.2% below this benchmark. Historically, Keros Therapeutics' own PB Ratio has ranged from 0.56 to 12.50 over the past decade. While the company's 10-year median is 4.25 vs. the industry median of 2.80, Keros Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keros Therapeutics's current PB Ratio of 0.75 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Keros Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current PB Ratio is 0.75, which is 82% below median its own 10-year median of 4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current PB Ratio of 0.75. The current PB Ratio is 0.75, which is 82% below median its 10-year median of 4.25 and 73.2% below the Biotechnology industry median of 2.80. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current PB Ratio is 0.75 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score
Get the complete analysis for KROS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
